Ethos Discovery now seeks to deliver a highly advanced clinical trial program investigating the use of novel drugs for the treatment of Hemangiosarcoma (HSA) with the goal of curing this aggressive cancer. This study will ask if drugs specifically matched to the genomic subtypes of patients with HSA will result in improved outcomes.

Intestinal dysbiosis has been associated with tumor progression of colorectal, lung, and breast cancer in human patients. The objective of this study is to determine whether or not canine patients diagnosed with osteosarcoma have intestinal dysbiosis and if the presence of intestinal dysbiosis is associated with metastasis in these patients.

We have previously reported on the tolerability and hints of clinical activity of Sorafenib in dogs with cancer. This background provides a rationale for the further study of Sorafenib in dogs with cancer. In this study we seek to define an optimal dosing schedule for Sorafenib and will assess its tolerability and activity in dogs with solid tumors.

This is study is looking to develop a novel diagnostic test for canine pancreatitis through the identification of genomic markers called exosomes.